| Description | Teneligliptin hydrobromide (MP-513 (hydrobromide)) is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. |
| Target activity | DPP4:1 nM |
| Synonyms | Teneligliptin hydrobromide anhydrous, MP-513 (hydrobromide) |
| molecular weight | 628.86 |
| Molecular formula | C22H30N6OS·5/2BrH |
| CAS | 906093-29-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 50 mg/mL (79.51 mM) Ethanol: 17 mg/mL (27.03 mM) H2O: 100 mg/mL (159.01 mM) |
| References | 1. Kishimoto M, et al. Diabetes Metab Syndr Obes. 2013, 6:187-95. 2. Sameshima A, et al. J Endocrinol. 2015, 227(1):25-36. 3. Ideta T, et al. Int J Mol Sci. 16(12):29207-18. 4. Pujadas G, et al. Endocrine. 2016, [Epub ahead of print]. |